US20050232978A1 - Delivery system for topical medications - Google Patents

Delivery system for topical medications Download PDF

Info

Publication number
US20050232978A1
US20050232978A1 US11153002 US15300205A US2005232978A1 US 20050232978 A1 US20050232978 A1 US 20050232978A1 US 11153002 US11153002 US 11153002 US 15300205 A US15300205 A US 15300205A US 2005232978 A1 US2005232978 A1 US 2005232978A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
composition
pad
active
dermatologically
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11153002
Inventor
Bhiku Patel
Mohan Vishnupad
Eugene Gans
Kuljit Bhatia
Original Assignee
Patel Bhiku G
Mohan Vishnupad
Gans Eugene H
Bhatia Kuljit S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying, e.g. spreading, media, e.g. remedies, on the human body ; Introducing media, e.g. remedies, into the body by diffusion through the skin
    • A61M35/003Hand-held applicator instruments having media dispensing or spreading means
    • A61M35/006Absorbent pads, e.g. swabs, containing a liquid, e.g. in a rupturable reservoir

Abstract

The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Description

    FIELD OF THE INVENTION
  • [0001]
    The present invention relates to drug delivery systems. In particular, it relates to such systems which comprise pads, sealed containers and liquid compositions.
  • BACKGROUND OF THE INVENTION
  • [0002]
    Dermatologically active ingredients for topical application to human skin are often insoluble solids (also called particulates) in media that are acceptable for skin application, e.g. without limitation, benzoyl peroxide (“BPO”), and insoluble antifungals. In order to prepare these topical products, dermatologically active ingredients are often suspended in the vehicle, which may be, for example without limitation, gels, creams, or lotions.
  • [0003]
    It is also desirable to have these types of dermatologically active ingredients placed on pads for delivery by wiping the pad on the skin. Pads may additionally be disposable for both convenience and sanitary reasons. However, several problems exist with this approach when it is applied to dermatologically active ingredients that are insoluble, minimally or weakly soluble.
  • [0004]
    First, the dermatologically active ingredient compositions, e.g. without limitation, BPO compositions, are not uniformly deposited on the pad. Second, the dermatologically active ingredient composition are not uniformly deposited on the skin during the wiping of the pad across the skin. Without uniformity, one cannot predict how much and whether any of the dermatologically active ingredient is delivered, and therefore, the delivery method is ineffective. Specified uniformity is preferred in most drug delivery systems.
  • [0005]
    Factors that are relevant to these problems include, that a portion of the liquid composition may preferentially squeeze through the fibers of the pad, leaving a high concentration of particulate dermatologically active ingredients on a surface of the pad. On the other hand, dermatologically active ingredient particles may preferentially squeeze through the fibers and leave particles on the walls of the container or in some parts of the pad or container, but not others.
  • [0006]
    Additionally, the container for a BPO pad, for example, may contribute to these problems. If the container is sealed with an alkaline based adhesive, BPO, a strong oxidizing agent, dissolves the adhesive after being in contact with BPO for as little as a month. The adhesive seal degrades and the two halves of the pouch come apart. Thus, there is also a need for a leak-proof container.
  • [0007]
    The use of pads stored in jars or large containers to apply single-phase solutions of dermatologically active ingredients has long been known as an effective technique. Because the dermatologically active ingredient is in solution, it remains acceptably distributed throughout the solvent vehicle, and is not susceptible to removal from the solution by filtration or adsorption by the pad.
  • [0008]
    The use of pads to apply single-phase suspensions of dermatologically active ingredients has been unsuccessful. The suspended dermatologically active ingredient tends to settle to the bottom of the container, resulting in unacceptable variations in dermatologically active ingredient concentration. This problem is aggravated by the tendency of pads to filter out or adsorb the suspended dermatologically active ingredient. Thus, even if the dermatologically active ingredient does not settle out of suspension, it can be collected on the pads unevenly. To make matters worse, having filtered or adsorbed the dermatologically active ingredient out of suspension, such pads have a tendency to retain the dermatologically active ingredient and not release it to the skin.
  • [0009]
    Oil-in-water and water-in-oil emulsions (e.g. without limitation creams and lotions) have been used as delivery vehicles for suspensions of dermatologically active ingredients (e.g. TRIAZ® of Medicis Pharmaceutical Corp. of Arizona) and work well when used alone as delivery vehicles. These creams and lotions hold the dermatologically active ingredients in suspension fairly well, resulting in even distribution of the dermatologically active ingredient throughout the vehicle, and thus on the skin.
  • [0010]
    However, when pads or pledgets are used to topically apply creams or lotions, several problems have been encountered. Creams have been found to adhere poorly to pads, and adhere all too well to the pad's container. Attempts to use pads as a delivery vehicle have resulted in the pads being used to wipe or scrape the cream or lotion off the container's walls so that it can be applied to the skin, and often the cream is incompletely released from the pad resulting in under-application of the dermatologically active ingredients. This has been a source of great frustration in the drug delivery art, as pads are a highly desirably method of topical application. For example, in the field of acne treatments, pads have been used for decades to apply solutions of salicylic acid (e.g. Stri-Dex® of Blistex Inc. of Illinois). On the other hand, benzoyl peroxide, which has been known for decades as a superior treatment for acne, has never been successfully marketed with a pad delivery system because it is not soluble and is delivered as a suspension in a cream or lotion. Thus, there is a great and long-standing demand for a way to topically deliver particle suspension of dermatologically active ingredients by way of a pad.
  • SUMMARY OF THE INVENTION
  • [0011]
    The present invention overcomes many of the problems experienced in the art. In this invention, the dermatologically active ingredients are insoluble drugs suitable for human or animal use, and the composition is a liquid comprising one or more dermatologically active ingredients. The composition is retained by the pad preferentially over the container. Dermatologically active ingredients, e.g. without limitation, BPO, and insoluble antifungals, do not preferentially migrate or adsorb from the composition (e.g. without limitation, emulsion) onto or into the pad, and therefore does not result in an uneven concentration of the dermatologically active ingredient in the composition versus the pad. Further, the pad is packaged in a container and one or more pads may be packaged in each container.
  • [0012]
    In this invention, pads include but are not limited to pads, pledgets, towels, towelettes, cloths, and sponges; the pads may be woven or nonwoven material. The dermatologically active ingredients in the invention can be any particulate or insoluble drugs including but not limited to drugs, prodrugs, cosmeceuticals, herbal medicines, traditional medicines, and active cosmetic ingredients, that are suitable for topical human use and are suspended and/or dispersed in a vehicle. Insoluble in this specification means insoluble or weakly or minimally soluble. Insoluble dermatologically active ingredients are often particulates.
  • [0013]
    In accordance with the present invention, insoluble dermatologically active ingredients are mixed in an emulsion composition, e.g. without limitation, an oil-in-water emulsion or a water-in-oil emulsion, preferably an oil-in-water emulsion. This composition is suited to causing the dermatologically active ingredient to be substantially uniformly distributed throughout the composition upon routine mixing during formulation, and remain so during the product's shelf life. The particle size may preferably be up to about 300 microns, more preferably about 10 to about 150 microns. For BPO, the most preferable particle size is less than about 50 microns. Further, the viscosity of the composition is carefully adjusted to be low enough that the composition will permeate the matrix of the pad's fibers and be held on the pad by capillary action. However, the viscosity must not be so low that the composition is so thin that it drains off the pad prematurely. On the other hand, if the viscosity is too high, not only will the composition fail to be taken into the pad's fibers' matrix, it will tend to be released from the surface of the pad to the walls of the container, and remain there, unavailable for application to the patient's skin.
  • [0014]
    Use of the present invention by wiping the pad across skin results in a transfer to the skin of the dermatologically active ingredient, meaning that the skin is substantially uniformly medicated. During this wiping, an adequate therapeutic dose of the dermatologically active ingredient is delivered to the skin. One advantage of this invention may be a reduced irritation to the skin as compared to similar compositions applied without the pad.
  • [0015]
    The composition may comprise one or more dermatologically active ingredients. The dermatologically active ingredient may be any drug effective in dermatological prevention or treatment, which is insoluble in the composition and is a particulate. An effective amount of the dermatologically active ingredient means an adequate therapeutic dose will be delivered to the skin by wiping the pad onto the skin.
  • [0016]
    The dermatologically active ingredient may be one or more dermatological drug which is insoluble in the composition, such as without limitation, drugs to treat or prevent acne, fungal infections, yeast infections, rosacea, photodamaged skin, hyperpigmented skin, eczema, allergic or contact dermatitis, seborrheic dermatitis, erythema, or psoriasis; salts or chelates, such as without limitation zinc oxide, iron EDTA, magnesium peroxide, ascorbyl linoleate; abrasives; active acids; active bases, such as without limitation minocycline; neutral actives, such as without limitation hydrocortisone; BPO; antifungals; antibacterials; corticosteroids; keratolytic agents; sulfur; sulfur-containing ingredients; or combinations thereof.
  • [0017]
    In one embodiment, soluble dermatologically active ingredients may additionally be present in the composition.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0018]
    FIG. 1 depicts the amount of composition associated with the pad and with the wall and void spaces of the container.
  • [0019]
    FIG. 2 is a ultra-violet photograph of Subject A in Test 2 after the composition was applied directly, not via a pad.
  • [0020]
    FIG. 3 is a ultra-violet photograph of Subject A in Test 2 after the composition was applied via the pad.
  • [0021]
    FIG. 4 is a ultra-violet photograph of Subject B in Test 2 after the composition was applied directly, not via a pad.
  • [0022]
    FIG. 5 is a ultra-violet photograph of a Subject B in Test 2 after the composition was applied via the pad.
  • DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • [0000]
    Pharmaceutical Compositions
  • [0023]
    One embodiment may comprise the composition with BPO as an dermatologically active ingredient, alone or in combination with other dermatologically active ingredients, in an oil-in-water emulsion. In one embodiment, the BPO particle size is less than about 50 microns, which provides substantially even coverage on the face and reduces the entrapment in the pad, e.g. without limitation, a non-woven pad. BPO in the composition may irritate sensitive skin and therefore, the composition may optionally comprise dimethicone, which may make the composition more acceptable for sensitive skin.
  • [0024]
    The composition may comprise one or more sulfur-containing ingredient as an dermatologically active ingredient, alone or in combination with other dermatologically active ingredients, in an oil-in-water emulsion in another embodiment. Sulfur-containing ingredients include without limitation sulfur and sulfacetamide.
  • [0025]
    An embodiment may comprise a composition with an insoluble antifungal as an dermatologically active ingredient alone or in combination with other dermatologically active ingredients, in an oil-in-water emulsion.
  • [0026]
    In one embodiment, the particle size of the dermatologically active ingredient may be reduced by milling the dermatologically active ingredient or end product, and/or the composition may have additional agents that substantially smooth the particle surface through a physical and/or chemical reaction. This may aid in substantially smooth application to the skin.
  • [0027]
    The composition of the present invention may be an oil-in-water emulsion with a viscosity of about 500 cps to about 7000 cps, more preferably about 2000 cps to about 3000 cps, and most preferably about 2200 cps. This viscosity is measured by a Brookfield viscometer LVT model at about 27° C. for sixty seconds. Most of the measurements were taken with a spindle set for 30 rpm, and some set for 12 rpm (if the composition was too thick for the 30 rpm), and then each was converted into cps. All of the viscosity measurements and limitations in this application are calculated in this same manner, unless otherwise specified.
  • [0000]
    Pads
  • [0028]
    Pads of this invention may be made of synthetic or natural material and woven or non-woven material, for example without limitation, BBA Nonwovens Product No. 149-273, which is 76 gsy (gsy means grams per square yard) of 46% rayon/54% polypropylene composite, 7 dot pattern, thermal bonded fabric made by BBA Nonwoven Division Bethune, S.C. Materials for the pad may comprise more than one layer.
  • [0029]
    In one embodiment, the pad is a non-woven material in a circular shape of 2.5 inches in diameter. The composition in this embodiment may be BPO in a oil-in-water emulsion.
  • [0030]
    In a preferred embodiment, the composition is an emulsion which is optimized to avoid demulsification when the composition is applied to the pad.
  • [0000]
    Containers
  • [0031]
    Packaging for the pad has an additional set of considerations. A container may contain one or more pads, does not leak the composition nor does it degrade excessively over time once it is sealed. The present invention may, for example without limitation, have a container comprised of a foil material with an inner plastic layer, such as Pechiney Corporation's of France packaging material composed of Varnish/ink/paper/LDPE/aluminum foil/Surlyn® (E.I. DuPont DeNemours & Co.); or Bomarko, Inc. of Indiana's packaging material composed of BLMG/LD/285F/MCMT. LDPE means low density polyethylene. In one embodiment of the invention, a container of foil material lined with a plastic was heat-sealed on four sides of a rectangle at 250° F. to 350° F. for a few seconds melting the plastic and forming a strong bond that remained intact for at least three (3) months under accelerated conditions (about 40° C. and 75% relative humidity), which typically corresponds to about 18 to about 24 months at room temperature (about 25° C.).
  • [0032]
    In an embodiment of the invention, the container may be any material that packages the pad with the composition and does not degrade or leak the composition for a sufficient period of time, such as shelf life of the invention. Preferably, the container comprises one or more sheets of plastic-lined foil material. The container is fashioned from the sheets to hold one or more pads. In one embodiment, two sheets, which are larger than the pad or the dimensions of the pad when folded, are placed in the following layers: a bottom sheet, the pad, and the top sheet over the pad. The sides of the sheets meet because the pad is smaller than the sheets and is placed in the center of the sheets. At the sides of the sheets, heat and pressure (preferably about 15 psi to about 40 psi) is applied which causes the plastic lining of both sheets to melt and seal together, enclosing the pad. One of ordinary skill in the art will understand that time, heat and pressure will vary according to the type of material and/or process used.
  • Further Embodiments and Parts Thereof
  • [0033]
    In one embodiment of the invention, the delivery system comprises a pad, a sealed container, and a composition, wherein the composition may be an emulsion which is substantially absorbed via capillary action to the pad, and the composition substantially remains on the pad in the container and a therapeutic amount of medication in the composition is discharged to the skin upon wiping the pad across the skin.
  • [0034]
    BPO is preferably 75% and sold under the trademarks Luperox A75FP/Lupersol 75FP by Atofina or Lucidol 75.
  • [0035]
    Table I depicts three embodiments (I, II, III) of the composition used in the present invention.
    TABLE 1
    I II III
    Dry flo starch 1 1 1
    Lucidol 75 Benzoyl peroxide 4.72 9.2 13.8
    75%
    Carbopol ultrez Carbomer 0.3 0.3 0.3
    10
    Versene NA Disodium EDTA 0.5 0.5 0.5
    Deionized water 71.78 67.3 62.6
    Glycerin 99% 6 6 6
    Sodium 0.3 0.3 0.3
    hydroxide pellets
    Puramex ZN Zinc lactate 0.2 0.2 0.2
    Glycopure 70% Glycolic acid 0.5 0.5 0.5
    Finsolve TN C12-C15 alkyl 7.1 7.1 7.1
    benzoate
    Cetearyl alcohol 2 2 2
    Dimethicone 1 1 1
    Arlacel 165 Glyceryl stearate & 1 1 1
    PEG 100 stearate
    Brij 72 Steareth 2 1.5 1.5 1.5
    Brij 78 Steareth 20 1 1 1
    Tween 20 Polysorbate 20 1.1 1.1 1.2
  • [0036]
    As is known in the art, the following definitions apply to this specification. EDTA means ethylenediamine tetraacetic acid. PEG means polyethylene glycol. BHT means butylated hydroxytoluene.
  • [0000]
    Test 1
  • [0037]
    FIG. 1 depicts the results of a test performed to see whether the BPO was excessively transferred from the pad to the inside of the container. Pads with compositions in Examples I (three times IA, IB, and IC), II (three times IIA, IIB, and IIC) and III (two times IIIA and IIIB) were sealed in containers. The sealed containers were weighed (“Total Weight”), then after opening, the pad was weighed (“Med Pad Wt”). “C” or “Wet Empty Pouch” was then calculated.
  • [0038]
    Then, the pads were soaked with acetonitrile to remove the emulsion and BPO. This was repeated twice, and then the pads were dried to a constant weight (“Dry Pad Wt”). The “Med on Pad” or the composition available for transfer from the pad to the skin was calculated. Then, the containers were rinsed and dried to constant weight (“Dry, Empty Pouch”). The weight of the composition left on the container and therefore unavailable to transfer to the skin was then calculated (“Med on Pouch Walls & Voids”). It is preferred that the ratio of (Med on Pad) to (Med on Pouch Walls & Voids) is 5 or greater.
  • [0000]
    Test 2
  • [0039]
    In a separate test, 0.15% (all percentages given in this specification are weight percentages unless otherwise specified) fluorescein sodium was added as a marker to compositions of Example I, to test whether the composition applies uniformly to the skin via the pad. Subjects were given the composition alone and asked to apply it to their faces and foreheads for comparison purposes.
  • [0040]
    In a separate procedure, subjects wiped the pads on their faces and foreheads. They were asked to use such pads in the same manner that they used other facial cleansing or medicated products. No other attempt was made to influence how the subjects were to wipe the skin.
  • [0041]
    Thirty minutes after each application (the composition alone and the composition via the pad), ultra-violet photographs were taken of the subject's face and foreheads. They showed substantially smooth and uniform deposition of the medication via the pad. FIG. 2 depicts Subject A after the composition was applied directly, and FIG. 3 depicts Subject A after the composition was applied via the pad. FIG. 2 shows that little or none of the composition was delivered to significant areas of the skin, and that there were isolated areas of excessive application. FIG. 3 shows that all areas where the subject applied the pad received sufficient composition.
  • [0042]
    FIG. 4 depicts Subject B after the composition was applied directly, and FIG. 5 depicts Subject B after the composition was applied via the pad. FIG. 4 shows that there were significant areas where little or no composition was delivered and several locations of clumps or excessive application. FIG. 5 shows that all areas where the subject applied the pad received sufficient composition.
  • [0000]
    Test 3
  • [0043]
    Separately, the pads were used to test whether acceptable levels of medication are applied to the skin from the pads. Regulatory boards and workers in the art have described an acceptable level of topical medication applied to the skin as being in the range of at least 2 mg of total medication, including the vehicle, covering each square centimeter of skin. In this test, subjects applied pads with Examples I and III to a prescribed area of the face in the same manner as they would normally use such medicated pads. To determine the amount of composition applied to this area of skin (which was 80 to 100 square centimeters), the pad was weighed before and after it was used. The weight of medication used was calculated and then divided by the area of skin.
  • [0044]
    For Example I pads, the mean dose of total composition delivered was 2.9 to 3.875 mg/cm2. For Example III, the mean dose of total composition delivered was 2.10 to 2.625 mg/cm2.
  • [0000]
    Test 4
  • [0045]
    Several sample embodiments of the present invention were also tested to obtain the viscosity. Each example was tested as described in paragraph 21. The results of these tests are as follows. Example I had a viscosity of 2000-2800 cps, Example II had a viscosity of 2000-2400 cps, Example III had a viscosity of 2000-2500 cps, and other compositions had the following viscosity.
    TABLE 2
    IV V VI VII
    Dry flo starch 1 1 1 1
    Lucidol 75 Benzoyl 4.72 4.72 9.2 13.8
    peroxide
    Carbopol ultrez Carbomer 0.3 0.3 0.3 0.3
    10
    Versene NA Disodium 0.5 0.5 0.5 0.5
    EDTA
    Deionized water 71.58 71.48 66.7 62.6
    Glycerin 96% 6 6 6 6
    Sodium 0.3 0.3 0.3 0.3
    hydroxide pellets
    Puramex ZN Zinc lactate 0.2 0.2 0.2 0.2
    Glycopure 70% Glycolic acid 0.5 0.5 0.5 0.5
    Finsolve TN C12-C15 alkyl 7.1 7.1 7.1 7.1
    benzoate
    Dimethicone 1 1 1 1
    Crodacol CS-50 Cetyl stearyl 2.3 2.4 2.2 2
    alcohol
    Arlacel 165 Glyceryl 1 1 1.5 1
    stearate &
    PEG 100
    stearate
    Brij 72 Steareth 2 1.5 1.5 1.5 1.5
    Brij 78 Steareth 20 1 1 1 1
    Tween 20 Polysorbate 20 1 1 1 1.2
    Viscosity (cps) 2200 6600 3400 2600
  • [0046]
    Additionally, the compositions of the present invention may be tested for viscosity in the following manner. A Brookfield viscometer model No. RVT with spindle #4 at 20 rpm for 60 seconds will be used at 25° C.+/−1° C. In this test, the compositions are preferably about 500 cps to about 10,000 cps, more preferably about 1900 cps to about 7000 cps, most preferably 4500 to about 6500 cps.
  • [0047]
    It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are evident from a review of the following claims.

Claims (2)

  1. 1-19. (canceled)
  2. 20. A drug delivery system comprising:
    a non-woven pad;
    a liquid composition, wherein the composition comprises benzoyl peroxide, starch, carbomer, disodium EDTA, water, glycerin, sodium hydroxide, zinc lactate, glycolic acid, C12-C15 alkyl benzoate, cetearyl alcohol, dimethicone, glyceryl stearate and PEG 100 stearate, steareth 2, steareth 20, and polysorbate 20; and
    a sealed container, wherein the container comprises a material comprised of metal substantially coated with one or more plastics on at least one surface, and one sheet of the material is heat sealed to a second sheet of the material, and the heat sealed materials contain the pad and the composition without leaking;
    wherein the composition has a viscosity of about 2000 cps to about 3000 cps; and wherein the composition has:
    about 1% starch;
    about 4% benzoyl peroxide;
    about 0.3% carbomer;
    about 0.5% disodium EDTA;
    about 71% water;
    about 6% glycerin;
    about 0.3% sodium hydroxide;
    about 0.2% zinc lactate;
    about 0.5% glycolic acid;
    about 7% C12-C15 alkyl benzoate;
    about 2% cetearyl alcohol;
    about 1% dimethicone;
    about 1% glyceryl stearate and PEG 100 stearate;
    about 1.5% steareth 2;
    about 1% steareth 20; and
    about 1% polysorbate 20.
US11153002 2003-07-03 2005-06-14 Delivery system for topical medications Abandoned US20050232978A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10613698 US7776355B2 (en) 2003-07-03 2003-07-03 Delivery system for topical medications
US11153002 US20050232978A1 (en) 2003-07-03 2005-06-14 Delivery system for topical medications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11153002 US20050232978A1 (en) 2003-07-03 2005-06-14 Delivery system for topical medications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10613698 Continuation US7776355B2 (en) 2003-07-03 2003-07-03 Delivery system for topical medications

Publications (1)

Publication Number Publication Date
US20050232978A1 true true US20050232978A1 (en) 2005-10-20

Family

ID=34103142

Family Applications (5)

Application Number Title Priority Date Filing Date
US10613698 Active 2026-06-11 US7776355B2 (en) 2003-07-03 2003-07-03 Delivery system for topical medications
US11153002 Abandoned US20050232978A1 (en) 2003-07-03 2005-06-14 Delivery system for topical medications
US11237013 Abandoned US20070196450A1 (en) 2003-07-03 2005-09-28 Delivery system for topical medications
US11651894 Abandoned US20070110794A1 (en) 2003-07-03 2007-01-09 Delivery system for topical medications
US13199491 Abandoned US20110313051A1 (en) 2003-07-03 2011-08-30 Delivery system for topical medications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10613698 Active 2026-06-11 US7776355B2 (en) 2003-07-03 2003-07-03 Delivery system for topical medications

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11237013 Abandoned US20070196450A1 (en) 2003-07-03 2005-09-28 Delivery system for topical medications
US11651894 Abandoned US20070110794A1 (en) 2003-07-03 2007-01-09 Delivery system for topical medications
US13199491 Abandoned US20110313051A1 (en) 2003-07-03 2011-08-30 Delivery system for topical medications

Country Status (6)

Country Link
US (5) US7776355B2 (en)
EP (1) EP1643947A4 (en)
JP (1) JP2007520436A (en)
CN (1) CN101072547A (en)
CA (1) CA2530402A1 (en)
WO (1) WO2005009322A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003034A1 (en) * 2004-07-02 2006-01-05 Bhatia Kuljit S Stable cleanser compositions containing sulfur
US20060004071A1 (en) * 2004-07-02 2006-01-05 Bhatia Kuljit S Triple anti-irritant composition
US20080026039A1 (en) * 2006-07-26 2008-01-31 Stiefel Laboratories, Inc. Benzoyl peroxide pads and formulations therefor

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226948A1 (en) 2009-03-05 2010-09-09 Medicis Pharmaceutical Corporation Methods and compositions for treating acne
WO2015061632A3 (en) * 2013-10-23 2015-10-29 O'connell John F Jr Antimicrobial compositions and articles
WO2016109517A1 (en) * 2014-12-29 2016-07-07 Kimberly-Clark Worldwide, Inc. Cosmetic emulsions

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852210A (en) * 1972-08-11 1974-12-03 Flow Pharma Inc Stable liquid detergent concentrates containing active oxygen
US4388301A (en) * 1981-06-12 1983-06-14 William H. Rorer, Inc. Method and composition for treating acne
US4545990A (en) * 1982-11-22 1985-10-08 L'oreal Anti-acne composition
US4735935A (en) * 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4803228A (en) * 1986-09-30 1989-02-07 L'oreal Unsaturated aromatic peroxides and their use in pharmaceutical and cosmetic compositions
US4891228A (en) * 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4906617A (en) * 1986-09-30 1990-03-06 L'oreal Pharmaceutical compositions containing saturated aromatic peroxides
US4917891A (en) * 1984-12-21 1990-04-17 Revlon, Inc. Composition having evaporative oil-like material
US4960772A (en) * 1988-03-09 1990-10-02 L'oreal Benzoyl peroxide and quaternary ammonium based pharmaceutical and cosmetic compositions
US4978695A (en) * 1988-05-16 1990-12-18 Mitsui Toatsu Chemicals, Incorporated Fine-particle aggregate emulsion and process for producing same
US5019567A (en) * 1987-11-24 1991-05-28 L'oreal Benzoyl peroxide--quaternary ammonium lipophilic salicylate based pharmaceutical and cosmetic compositions and their use especially in treatment of acne
US5254109A (en) * 1992-12-07 1993-10-19 Creative Products Resource Associates, Ltd. Separately packaged applicator pads for topical delivery of incompatable drugs
US5344971A (en) * 1992-10-15 1994-09-06 L'oreal Process for deodorizing a mercapto acid by extracting malodorous compound therefrom with a supercritical fluid
US5368581A (en) * 1992-12-07 1994-11-29 Creative Products Resource Associates, Ltd. Method of using a packaging system with folded applicator pads for topical drug delivery
US5387363A (en) * 1992-06-02 1995-02-07 Elf Atochem North America, Inc. Water in oil emulsions
US5409706A (en) * 1992-05-04 1995-04-25 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5466456A (en) * 1991-11-27 1995-11-14 Glover; Morris S. Facial cleanser
US5470884A (en) * 1994-05-19 1995-11-28 Procter & Gamble Anti-acne compositions
US5632996A (en) * 1995-04-14 1997-05-27 Imaginative Research Associates, Inc. Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use
US5660839A (en) * 1994-07-11 1997-08-26 L'oreal Nongreasy/nonsticky fatty cosmetic/dermatological compositions
US5690946A (en) * 1994-07-22 1997-11-25 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5756119A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5767098A (en) * 1985-12-12 1998-06-16 Dermik Laboratories, Inc. Anti-acne method and composition
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5821209A (en) * 1997-02-25 1998-10-13 Elf Atochem North America, Inc. Water in oil emulsions containing a terpene, benzyl alcohol, and wax
US5849834A (en) * 1996-03-12 1998-12-15 Shiseido Co., Ltd. W/O type emulsified composition and cosmetic
US5874074A (en) * 1992-12-16 1999-02-23 Creative Products Resource Associates Inc. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5880079A (en) * 1994-06-17 1999-03-09 The Procter & Gamble Company Bleaching compositions
US5951991A (en) * 1997-05-22 1999-09-14 The Procter & Gamble Company Cleansing products with improved moisturization
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
US6001380A (en) * 1994-04-12 1999-12-14 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US6017549A (en) * 1997-09-30 2000-01-25 E-L Management Corp. Non-irritating cosmetic and pharmaceutical compositions
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US6149926A (en) * 1996-10-07 2000-11-21 The Procter & Gamble Company Cosmetic applicators which contain stable oil-in-water emulsions
US6153208A (en) * 1997-09-12 2000-11-28 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US20020086039A1 (en) * 1999-12-07 2002-07-04 Sean Lee New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US6455076B1 (en) * 1994-12-21 2002-09-24 Gary S. Hahn Formulations and methods for reducing skin irritation
US6462025B2 (en) * 2000-12-12 2002-10-08 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US6469227B1 (en) * 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US20030031727A1 (en) * 1994-12-21 2003-02-13 Cosmederm Technologies, Llc Topical product formulations containing strontium for reducing skin irritation
US6784145B2 (en) * 2001-06-22 2004-08-31 L'oreal Cosmetic and dermatological article comprising N-(3-chloroallyl) hexaminium chloride
US6861397B2 (en) * 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535422A (en) * 1968-03-11 1970-10-20 Stiefel Laboratories Stable benzoyl peroxide composition
US4056611A (en) * 1973-04-16 1977-11-01 Stiefel Laboratories, Inc. Therapeutic composition
US4387107A (en) * 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4593046A (en) * 1983-07-15 1986-06-03 Murray Gruber Method of reducing skin irritation from benzoyl peroxide
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5036108A (en) * 1988-12-14 1991-07-30 Kao Corporation Water-in-oil emulsion cosmetic
JPH07504168A (en) * 1992-02-18 1995-05-11
WO1994002674A1 (en) * 1992-07-27 1994-02-03 The Procter & Gamble Company Laminated dual textured treatment pads
US5460620A (en) 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
US5242433A (en) * 1992-12-07 1993-09-07 Creative Products Resource Associates, Ltd. Packaging system with in-tandem applicator pads for topical drug delivery
WO1995023587A1 (en) 1994-03-03 1995-09-08 The Procter & Gamble Company Anti-acne compositions
US5720948A (en) * 1995-11-07 1998-02-24 Helene Curtis Inc. Non-ionic surfactant emulsion vehicles and their use for deposition of drug into and across skin
JP2003093152A (en) * 2001-09-26 2003-04-02 Lion Corp Cosmetics impregnated sheet
US6943197B2 (en) * 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses

Patent Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852210A (en) * 1972-08-11 1974-12-03 Flow Pharma Inc Stable liquid detergent concentrates containing active oxygen
US4388301A (en) * 1981-06-12 1983-06-14 William H. Rorer, Inc. Method and composition for treating acne
US4545990A (en) * 1982-11-22 1985-10-08 L'oreal Anti-acne composition
US4917891A (en) * 1984-12-21 1990-04-17 Revlon, Inc. Composition having evaporative oil-like material
US5767098A (en) * 1985-12-12 1998-06-16 Dermik Laboratories, Inc. Anti-acne method and composition
US4735935A (en) * 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4803228A (en) * 1986-09-30 1989-02-07 L'oreal Unsaturated aromatic peroxides and their use in pharmaceutical and cosmetic compositions
US4906617A (en) * 1986-09-30 1990-03-06 L'oreal Pharmaceutical compositions containing saturated aromatic peroxides
US5019567A (en) * 1987-11-24 1991-05-28 L'oreal Benzoyl peroxide--quaternary ammonium lipophilic salicylate based pharmaceutical and cosmetic compositions and their use especially in treatment of acne
US4891228A (en) * 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4960772A (en) * 1988-03-09 1990-10-02 L'oreal Benzoyl peroxide and quaternary ammonium based pharmaceutical and cosmetic compositions
US4978695A (en) * 1988-05-16 1990-12-18 Mitsui Toatsu Chemicals, Incorporated Fine-particle aggregate emulsion and process for producing same
US5756119A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US5466456A (en) * 1991-11-27 1995-11-14 Glover; Morris S. Facial cleanser
US5409706A (en) * 1992-05-04 1995-04-25 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
US5387363A (en) * 1992-06-02 1995-02-07 Elf Atochem North America, Inc. Water in oil emulsions
US5344971A (en) * 1992-10-15 1994-09-06 L'oreal Process for deodorizing a mercapto acid by extracting malodorous compound therefrom with a supercritical fluid
US5417674A (en) * 1992-12-07 1995-05-23 Creative Products Resource Associates, Ltd. Separately packaged applicator pads for topical delivery of incompatible drugs
US5254109A (en) * 1992-12-07 1993-10-19 Creative Products Resource Associates, Ltd. Separately packaged applicator pads for topical delivery of incompatable drugs
US5368581A (en) * 1992-12-07 1994-11-29 Creative Products Resource Associates, Ltd. Method of using a packaging system with folded applicator pads for topical drug delivery
US5562642A (en) * 1992-12-07 1996-10-08 Creative Products Resource, Inc. Separately packaged applicator pads for topical delivery of incompatible drugs
US5874074A (en) * 1992-12-16 1999-02-23 Creative Products Resource Associates Inc. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US6001380A (en) * 1994-04-12 1999-12-14 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5470884A (en) * 1994-05-19 1995-11-28 Procter & Gamble Anti-acne compositions
US5880079A (en) * 1994-06-17 1999-03-09 The Procter & Gamble Company Bleaching compositions
US5660839A (en) * 1994-07-11 1997-08-26 L'oreal Nongreasy/nonsticky fatty cosmetic/dermatological compositions
US5997885A (en) * 1994-07-22 1999-12-07 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US5690946A (en) * 1994-07-22 1997-11-25 L'oreal Cosmetic and/or dermatological composition containing thermal spring water or mineral water and an active agent, in order to combat acne or aging
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US20030031727A1 (en) * 1994-12-21 2003-02-13 Cosmederm Technologies, Llc Topical product formulations containing strontium for reducing skin irritation
US6455076B1 (en) * 1994-12-21 2002-09-24 Gary S. Hahn Formulations and methods for reducing skin irritation
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5632996A (en) * 1995-04-14 1997-05-27 Imaginative Research Associates, Inc. Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5849834A (en) * 1996-03-12 1998-12-15 Shiseido Co., Ltd. W/O type emulsified composition and cosmetic
US6149926A (en) * 1996-10-07 2000-11-21 The Procter & Gamble Company Cosmetic applicators which contain stable oil-in-water emulsions
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
US5821209A (en) * 1997-02-25 1998-10-13 Elf Atochem North America, Inc. Water in oil emulsions containing a terpene, benzyl alcohol, and wax
US5951991A (en) * 1997-05-22 1999-09-14 The Procter & Gamble Company Cleansing products with improved moisturization
US6153208A (en) * 1997-09-12 2000-11-28 The Procter & Gamble Company Cleansing and conditioning article for skin or hair
US6017549A (en) * 1997-09-30 2000-01-25 E-L Management Corp. Non-irritating cosmetic and pharmaceutical compositions
US6183766B1 (en) * 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
US6861397B2 (en) * 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface
US20020086039A1 (en) * 1999-12-07 2002-07-04 Sean Lee New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US6469227B1 (en) * 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US6462025B2 (en) * 2000-12-12 2002-10-08 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US6784145B2 (en) * 2001-06-22 2004-08-31 L'oreal Cosmetic and dermatological article comprising N-(3-chloroallyl) hexaminium chloride
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003034A1 (en) * 2004-07-02 2006-01-05 Bhatia Kuljit S Stable cleanser compositions containing sulfur
US20060004071A1 (en) * 2004-07-02 2006-01-05 Bhatia Kuljit S Triple anti-irritant composition
US20060093682A1 (en) * 2004-07-02 2006-05-04 Bhatia Kuljit S Stable cleanser compositions containing sulfur
US20060093683A1 (en) * 2004-07-02 2006-05-04 Bhatia Kuljit S Stable cleanser compositions containing sulfur
US20110223261A1 (en) * 2004-07-02 2011-09-15 Medicis Pharmaceutical Corporation Stable cleanser compositions containing sulfur
US20080213409A1 (en) * 2004-07-02 2008-09-04 Bhatia Kuljit S Triple anti-irritant composition
US7479289B2 (en) 2004-07-02 2009-01-20 Medicis Pharmaceutical Corporation Stable cleanser compositions containing sulfur
US20090074888A1 (en) * 2004-07-02 2009-03-19 Bhatia Kuljit S Stable cleanser compositions containing sulfur
US7655682B2 (en) 2004-07-02 2010-02-02 Medicis Pharmaceutical Corporation Triple anti-irritant composition
US7674812B2 (en) 2004-07-02 2010-03-09 Medicis Pharmaceutical Corp. Triple anti-irritant composition
US20080026039A1 (en) * 2006-07-26 2008-01-31 Stiefel Laboratories, Inc. Benzoyl peroxide pads and formulations therefor

Also Published As

Publication number Publication date Type
EP1643947A2 (en) 2006-04-12 application
US20110313051A1 (en) 2011-12-22 application
US20050100585A1 (en) 2005-05-12 application
WO2005009322A3 (en) 2005-08-04 application
WO2005009322A2 (en) 2005-02-03 application
JP2007520436A (en) 2007-07-26 application
US20070196450A1 (en) 2007-08-23 application
CA2530402A1 (en) 2005-02-03 application
US7776355B2 (en) 2010-08-17 grant
CN101072547A (en) 2007-11-14 application
EP1643947A4 (en) 2007-07-25 application
US20070110794A1 (en) 2007-05-17 application

Similar Documents

Publication Publication Date Title
US5500222A (en) Transdermal administration of oxybutynin
US4810499A (en) Transdermal drug delivery system and method
US5133972A (en) Topically administrable pharmaceutical preparations
US5876745A (en) Method for preparing a medical adhesive sheet
US4927687A (en) Sustained release transdermal drug delivery composition
US4834978A (en) Method of transdermal drug delivery
US6756520B1 (en) Hydrophilic compositions for use on absorbent articles to enhance skin barrier
US5965154A (en) Adhesive matrix type transdermal patch and method of manufacturing same
US6893655B2 (en) Transdermal delivery devices
US5702721A (en) Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof
US20030082217A1 (en) Use of heat-stabilizing microcapsules to improve the activity or penetration of cosmetic or pharmaceutical active principles
US4263363A (en) Emulsion-containing absorbent article having improved water holding capacity
US4910205A (en) Transdermal delivery of loratadine
US20030077307A1 (en) Film-forming compositions for protecting skin from body fluids and articles made therefrom
US6287581B1 (en) Absorbent articles providing skin health benefits
US6534074B2 (en) Absorbent articles providing skin health benefits
US6328992B1 (en) Cannabinoid patch and method for cannabis transdermal delivery
US3830198A (en) Device for providing treated sheet-like materials
US20050129651A1 (en) Sanitary napkins with hydrophobic lotions
US5470563A (en) Alleviating skin irritation resulting from applying tacky tapes
Venkatraman et al. Skin adhesives and skin adhesion: 1. Transdermal drug delivery systems
US20060206077A1 (en) Absorbent article having barrier sheet against the transfer of the skin care composition
US20050191337A1 (en) Patch with a magnetic field effect
US3731683A (en) Bandage for the controlled metering of topical drugs to the skin
US6455065B1 (en) Therapeutic method for treating acne or isolated pimples and adhesive patch therefor